Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY

Dr Reddy's Laboratories Stock Analysis & Ratings

Dr Reddy's Laboratories Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Dr Reddy's Laboratories stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

RDY

RDY Stock Stats

Previous Close$63.39
Open$62.91
Bid52 x 100
Ask0 x 0
Today’s Range$62.46 - $63.12
52-Week Range$57.54 - $75.50
Volume105.25K
Average Volume127.68K
Market Cap$10.39B
Beta0.47
P/E Ratio35.8
EPS1.75
Earnings DateJan 28, 2022
Dividend & Yield0.56 (0.9%)
Ex-Dividend DateJul 30, 2021

Company Description

Dr. Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Erez Israeli
Employees
22,739
Website
www.drreddys.com
ISIN
US2561352038
Address
8-2-337, Road No. 3, Hyderabad, TG, 500 034, IN

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

RDY FAQ

What was Dr Reddy's Laboratories’s price range in the past 12 months?
Dr Reddy's Laboratories lowest stock price was $57.54 and its highest was $75.50 in the past 12 months.
    What is Dr Reddy's Laboratories’s market cap?
    Dr Reddy's Laboratories’s market cap is $10.39B.
      What is Dr Reddy's Laboratories’s price target?
      The average price target for Dr Reddy's Laboratories is $80.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $80.00 ,the lowest forecast is $80.00. The average price target represents 27.71% Increase from the current price of $62.64.
        What do analysts say about Dr Reddy's Laboratories?
        Dr Reddy's Laboratories’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Dr Reddy's Laboratories’s upcoming earnings report date?
          Dr Reddy's Laboratories’s upcoming earnings report date is Jan 28, 2022 which is in 12 days.
            How were Dr Reddy's Laboratories’s earnings last quarter?
            Dr Reddy's Laboratories released its earnings results on Oct 29, 2021. The company reported $0.797 earnings per share for the quarter, beating the consensus estimate of $0.562 by $0.235.
              Is Dr Reddy's Laboratories overvalued?
              According to Wall Street analysts Dr Reddy's Laboratories’s price is currently Undervalued.
                Does Dr Reddy's Laboratories pay dividends?
                Dr Reddy's Laboratories pays a Annually dividend of $0.28 which represents an annual dividend yield of 0.9%. Dr Reddy's Laboratories’s last Annually dividend payment was on Aug 11, 2021. Dr Reddy's Laboratories’s upcoming ex-dividend date is Jul 30, 2021
                  What is Dr Reddy's Laboratories’s EPS estimate?
                  Dr Reddy's Laboratories’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Dr Reddy's Laboratories have?
                  Dr Reddy's Laboratories has 165,890,000 shares outstanding.
                    What happened to Dr Reddy's Laboratories’s price movement after its last earnings report?
                    Dr Reddy's Laboratories reported an EPS of $0.797 in its last earnings report, beating expectations of $0.562. Following the earnings report the stock price went up 4.077%.
                      Which hedge fund is a major shareholder of Dr Reddy's Laboratories?
                      Among the largest hedge funds holding Dr Reddy's Laboratories’s share is Causeway Capital Management LLC. It holds Dr Reddy's Laboratories’s shares valued at 5M.

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis